Alkylating agents and fludarabine for Waldenstrom's macroglobulinaemia
A Cochrane review 1 included 1 study with a total of 92 subjects. The effect of fludarabine was compared to the combination of cyclophosphamide (the alkylating agent), doxorubicin and prednisone (CAP) in patients with pretreated/relapsed WM. Compared to CAP, the Hazard ratio (HR) for deaths of treatment with fludarabine was estimated to be 1.04, with a standard error of 0.30 (95% CI 0.58 to 1.48) The mean difference of median survival time was -4.00 months, and 16.00 months for response duration in favour of fludarabine. The relative risks (RR) of response rate was 2.80 (95% CI 1.10 to 7.12).
Comment: The quality of evidence is downgraded by study quality (inadequate or unclear allocation concealment) and by imprecise results (few patients and wide confidence intervals).
1. Yang K, Tan J, Wu T. Alkylating agents for Waldenstrom's macroglobulinaemia. Cochrane Database Syst Rev 2009 Jan 21;(1):CD006719. [PMID:19160296]
Copyright © 2021 Duodecim Medical Publications Limited.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Complete Product Information.